Titin antibody in myasthenia gravis and its clinical significance

Xiang Jun Chen,Jian Qiao,Chuanzhen Lü
2000-01-01
Abstract:Objective: To investigate the clinical significance of titin antibody (titinab) in myasthenia gravis(MG). Methods: Recombinant MGT-30 peptide was synthesized by genetic engineering technique. We had examined titinab in the sera of 141 MG patients with different thymic pathology(MG group), 265 normal controls (NC group) and 36 diseased controls without MG(NMG group) using recombinant MGT-30 as antigen of ELISA. Acetylcholine receptor antibody(AChRab) and presynaptic membrane receptor antibody(PrsmRab) were parallelly examined in MG patients. Results: The titer of titinab in the sera of MG patients was significantly higher than those of NC group and NMG group (P < 0.01) and the positive rate of titinab was 83.7% in 49 MG patients with thymoma(MGT), 43.2% in 44 MG with thymic atrophy(MGA), however, all were negative in 38 MG with thymic hyperplasia(MGH) and 10 MG with normal thymic histology(MGN). In NMG group, only a 38-aged female patient with polymyositis and hyperthyroidism appeared positive. There was a significant correlation between the titer of titinab and the severity of the muscular weakness in MGH patients(P < 0.01), and the titer of titinab in sere of MGT patients was also significantly correlated to the serum level of AChRab and PrsmRab(P < 0.01). Conclusion: Recombinant MGT-30 peptide can be used as antigen to detect titinab in MG patients. The determined level of titinab should be a helpful parameter in differential diagnosis of MGT prior to operation, and its function and role in the pathogenesis of MGT and MGA will be studied further.
What problem does this paper attempt to address?